|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/00 | (2006.01) |
| A61K 38/22 | (2006.01) | ||
| A61B 5/00 | (2006.01) | ||
| A61P 9/00 | (2006.01) | ||
| A61P 11/00 | (2006.01) | ||
| A61P 9/04 | (2006.01) |
| (11) | Number of the document | 3154559 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15730858.6 |
| Date of filing the European patent application | 2015-06-10 | |
| (97) | Date of publication of the European application | 2017-04-19 |
| (45) | Date of publication and mention of the grant of the patent | 2021-09-01 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/IB2015/054399 |
| Date | 2015-06-10 |
| (87) | Number | WO 2015/189790 |
| Date | 2015-12-17 |
| (30) | Number | Date | Country code |
| 201462011744 P | 2014-06-13 | US |
| (72) |
PRESCOTT, Margaret Forney , US
ZHANG, Yiming , US
DAHLKE, Marion , CH
SEVERIN, Thomas , CH
|
| (73) |
Novartis AG ,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | USE OF SERELAXIN TO REDUCE GDF-15 |
| USE OF SERELAXIN TO REDUCE GDF-15 |